Caisse DE Depot ET Placement DU Quebec Purchases 46,349 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Caisse DE Depot ET Placement DU Quebec increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 13.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 390,093 shares of the biotechnology company's stock after buying an additional 46,349 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned 0.87% of United Therapeutics worth $137,640,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of UTHR. Cerity Partners LLC raised its position in United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after purchasing an additional 2,702 shares during the last quarter. Milestone Asset Management LLC lifted its position in United Therapeutics by 56.5% during the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company's stock worth $1,014,000 after buying an additional 1,037 shares in the last quarter. Korea Investment CORP grew its holdings in United Therapeutics by 6.2% during the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after acquiring an additional 2,300 shares during the last quarter. Janney Montgomery Scott LLC increased its position in United Therapeutics by 9.1% in the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company's stock valued at $3,326,000 after acquiring an additional 789 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of United Therapeutics by 35.4% in the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company's stock worth $68,999,000 after acquiring an additional 50,291 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Trading Down 2.1 %

Shares of NASDAQ UTHR traded down $6.39 during mid-day trading on Tuesday, hitting $292.32. The company had a trading volume of 87,802 shares, compared to its average volume of 441,077. United Therapeutics Co. has a one year low of $256.08 and a one year high of $417.82. The company has a market capitalization of $13.18 billion, a PE ratio of 12.84, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. The firm has a 50-day simple moving average of $301.56 and a two-hundred day simple moving average of $343.64.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same quarter last year, the firm posted $6.17 EPS. The company's quarterly revenue was up 17.2% on a year-over-year basis. Sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the sale, the executive vice president now owns 36,781 shares of the company's stock, valued at $11,261,606.58. This trade represents a 23.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $896,950.62. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 75,500 shares of company stock worth $24,245,880 over the last 90 days. Company insiders own 11.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on UTHR shares. UBS Group raised their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. JPMorgan Chase & Co. cut their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Bank of America raised United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price on the stock in a research note on Monday, April 21st. Finally, StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $392.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.